The University of Rochester’s Wilmot Cancer Institute has officially joined the ranks of the nation’s top cancer centers, earning the prestigious National Cancer Institute (NCI) designation. The announcement marks a historic milestone for the Finger Lakes and Central New York, with the institute now positioned to receive $10 million in federal funding over five years to expand cancer research, clinical trials, and patient care.
With this new status, Wilmot becomes the 73rd NCI-Designated Cancer Center in the U.S.—a title held by only the top 4 percent of cancer centers nationwide.
“This is not a finish line—it’s a new beginning,” said Dr. Jonathan Friedberg, director of the Wilmot Cancer Institute. “We are committed to leveraging this designation to increase clinical trial availability for our patients and decrease suffering from cancer throughout our region.”
The NCI designation recognizes institutions with the highest levels of excellence in cancer research, treatment, and community outreach. Wilmot serves more than three million people across 27 counties in western and central New York—an area marked by high cancer rates, aging populations, and rural health challenges.
Wilmot’s new designation opens the door for expanded access to advanced clinical trials, state-of-the-art technology, and additional outreach programs focused on prevention and care in underserved communities.
At a press conference celebrating the designation, elected leaders emphasized the regional impact. “The Wilmot Cancer Institute is Upstate New York’s largest cancer provider and one of the top cancer research centers in the country,” said Senator Chuck Schumer, who personally lobbied for the designation. “This will boost Wilmot’s capacity to treat patients and conduct research, while enhancing its ability to recruit top cancer investigators.”
Senator Kirsten Gillibrand called the recognition a “testament to groundbreaking clinical research and lifesaving treatments,” while Congressman Joe Morelle described it as a deeply personal milestone, recalling the care Wilmot provided for his late daughter.
Wilmot has grown significantly since Friedberg became director in 2013, expanding to 13 locations and establishing research programs focused on cancer prevention, genetics, and the tumor microenvironment. Its scientists and clinicians have contributed to landmark advances, including the HPV vaccine and modern anti-nausea treatments.
Now, with NCI designation in hand, Wilmot plans to build new facilities, launch a drug-development program, and expand its network across the state.
“This is a great day for the University of Rochester and the Wilmot Cancer Institute,” said University President Sarah Mangelsdorf. “We celebrate as we head down a new path to removing the burden of cancer in our community.”
FingerLakes1.com is the region’s leading all-digital news publication. The company was founded in 1998 and has been keeping residents informed for more than two decades. Have a lead? Send it to [email protected].